NEW OPPORTUNITIES IN MANAGEMENT OF PREMATURE OVARIAN INSUFFICIENCY


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The review presents large-scale worldwide researches on using of androgens in patients with different stages of ovarian aging. Current understandings of pathogenic mechanisms lead to successful outcomes of these hormones use are explained.

Full Text

Restricted Access

About the authors

N. N SHAMILOVA

V.I. Kulakov Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of the Russian Federation

Email: n_shamilova@oparina4.ru
Moscow, Russia

L. A MARCHENKO

V.I. Kulakov Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of the Russian Federation

Email: l_marchenko@oparina4.ru
Moscow, Russia

G. I TABEEVA

V.I. Kulakov Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of the Russian Federation

Moscow, Russia

References

  1. Практические рекомендации. Ведение женщин в пери-и постменопаузе. М.: ФГБУ «Научный центр акушерства, гинекологии и перинатологии им. академика В.И. Кулакова»; 2010: 32-3.
  2. Anderiesz C., Trounson A.O. The effect of testosterone on the maturation and development capacity of murine oocytes in vitro. Hum. Reprod. 1995; 10: 2377-81.
  3. Andux S., Ellis R.E. Apoptosis maintains oocyte quality in aging Caenorhabditis elegans females. PLoS Genet. 2008; 4(12): e1000295.
  4. Barad D., Gleicher N. Effect of dehydroepinadrosterone on oocytes and embryo yields, embryo grade and cell number in IVF. Hum. Reprod. 2006; 21: 2845-9.
  5. Barad D.H., Brill H., Gleicher N. Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function. J. Assist. Reprod. Genet. 2007; 24: 629-34.
  6. Barad D.H., Gleicher N. Increased oocytes production after treatment with dehydroepiandrosterone. Fertil. Steril. 2005; 84: 756; e1-3.
  7. Barad D.H., Weghofer A., Gleicher N. Comparing anti-Mullerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function. Fertil. Steril. 2009; 91(Suppl. 4): 1553-5.
  8. Broekmans F.J., Soules M.R., Fauser B.C. Ovarian aging: mechanisms and clinical consequences. Endocr. Rev. 2009; 30: 465-93.
  9. Buster J.E. Transvaginal dehydroepiandrosterone: An unconventional proposal to deliver a mysterious androgen that has no receptor or target tissue using a strategy with a new name: Hormone precursor replacement therapy (HPRT). Menopause. 2009; 16(5): 858-9.
  10. Casson P.R., Santoro N., Elkind-Hirsch K., Carson S.A., Hornsby P.J., Abraham G., Buster J.E. Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-I and decreases high-density lipoprotein: a six-month trial. Fertil. Steril. 1998; 70: 107-10.
  11. Coccia M.E., Rizzello F. Ovarian reserve. Ann. N. Y. Acad. Sci. 2008; 1127: 27-30.
  12. Conway G.S., Kaltsas G., Patel A., Davies M.C., Jacobs H.S. Characterization of idiopathic premature ovarian failure. Fertil. Steril. 1996; 65(2): 337-41.
  13. Eppig J.J., Freter R.R., Ward Bailey P.F., Schultz R.M. Inhibition of oocyte maturation in the mouse: participation of cAMP, steroid hormone, and a putative maturation-inhibitory factor. Dev. Biol. 1983; 100: 39-49.
  14. Faddy M.J., Gosden R.G. A mathematical model of follicle dynamics in the human ovary. Hum. Reprod. 1995; 10(4): 770-5.
  15. Fraisse T., Ibecheole V., Streuli I., Bischof P., de Ziegler D. Undetectable serum anti-Mullerian hormone levels and occurrence of ongoing pregnancy. Fertil. Steril. 2008; 89(3): 711-29.
  16. Gleiche rN., Ryan E., Weghofer A., Blanco-Mejia S., Barad D.H. Miscarriage rates after dehydroepiandrosterone (DHEA) supplementation in women with diminished ovarian reserve: a case control study. Reprod. Biol. Endocrinol. 2009; 7: 108.
  17. Gleicher N., Weghofer A., Barad D. Increased euploid embryos after supplementation with dehydroepiandrosterone (DHEA) in women with premature ovarian aging. Fertil. Steril. 2007; 88(Suppl. 1) :S232.
  18. Gleicher N., WeghoferA., Barad D.H. Anti-Mullerian hormone (AMH) defines, independent of age, low versus good livebirth chances in women with severely diminished ovarian reserve. Fertil. Steril. 2010; 94(7): 2824-7.
  19. Gleicher N., Weghofer A., Barad D.H. Dehydroepiandrosterone (DHEA) reduces embryo aneuploidy: direct evidence from preimplantation genetic screening (PGS). Reprod. Biol. Endocrinol. 2010; 8: 140.
  20. Gleicher N., Barad D.H. Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR). Reprod. Biol. Endocrinol. 2011; 9: 67.
  21. Hansen K.R., Knowlton N.S., Thyer A.C., Charleston J.S., Soules M.R., Klein N.A. A new model of reproductive aging: the decline in ovarian non-growing follicle number from birth to menopause. Hum. Reprod. 2008; 23(3): 699-708.
  22. Heijnen E.M., Eijkemans M.J., Hughes E.G., Laven J.S., Macklon N.S., Fauser B.C. A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome. Hum. Reprod. Update. 2006; Hodges C.A., Ilagan A., Jenninger D., Keri R., Nilson J., Hunt P.A. Experimental evidence that changes in oocyte growth influence meiotic chromosome segregation. Hum. Reprod. 2002; 17: 1171-80.
  23. La Marca A., Marzotti S., Brozzetti A., Stabile G., Artenisio A.C., Bini V. et al. Primary ovarian insufficiency due to steroidogenic cell autoimmunity is associated with a preserved pool of functioning follicles. J. Clin. Endocrinol. Metab. 2009; 94(10): 3816-23.
  24. Labrie F., Archer D., Bouchard C., Fortier M., Cusan L., Gomez J.L. et al. Serum steroid levels during 12week intravaginal dehydroepiandrosterone administration. Menopause. 2009; 16: 897-906.
  25. Labrie F. DHEA, important source of sex steroids in men and even more in women. Prog. Brain Res. 2010; 182: 97-148.
  26. Labrie F., Archer D., Bouchard C., Fortier M., Cusan L., Gomez J.L. et al. Intravaginal dehydroepiandrosterone (prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause. 2009; 16: 907-22.
  27. Labrie F., Archer D., Bouchard C., Fortier M., Cusan L., Gomez J.L. et al. Effect on intravaginal dehydroepi-androsterone (prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause. 2009; 16: 923-31.
  28. Labrie F., Bélanger A., Bélanger P., Berube R., Martel C., Cusan L. et al. Metabolism of DHEA in postmenopausal women following percutaneous administration. J. Steroid Biochem. Mol. Biol. 2007; 103(2): 178-88.
  29. Labrie F., Bélanger A., Cusan L., Séguin C., Pelletier G., Kelly P.A. et al. Antifertility effects of LHRH agonists in the male. J. Androl.1980; 1: 209-28.
  30. Labrie F., Bélanger A., Luu-The V., Labrie C., Simard J., Cusan L., et al. DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: Its role during aging. Steroids. 1998; 63(5-6): 322-8.
  31. Labrie F., Dupont A., Bélanger A. Complete androgen blockade for the treatment of prostate cancer. In: de Vita V.T., Hellman S., Rosenberg S.A., eds. Important advances in oncology. Philadelphia: J. B. Lippincott; 1985: 193-217.
  32. Labrie F., Luu-The V., Labrie C., Bélanger A., Simard J., Lin S. -X. et al. Endocrine and intracrine sources of androgens in women: Inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr. Rev. 2003; 24(2): 152-82.
  33. Labrie F., Luu-The V., Lin S.-X., Simard J., Labrie C. Role of 17b-hydroxysteroid dehydrogenases in sex steroid formation in peripheral intracrine tissues. Trends Endoclinol. Metab. 2000; 11(10): 421-7.
  34. Lenie S., Smitz J. Functional AR signaling is evident in an in vitro mouse follicle culture bioassay that encompasses most stages of folliculogenesis. Biol. Reprod. 2009; 80:685-95.
  35. Luchetti C.G., Solano M.E., Sander V., Arcos M.L., Gonzalez C., Di Girolamo G. et al. Effects of dehydroepiandrosterone on ovarian cystogenesis and immune function. J. Reprod. Immunol. 2004; 64: 59-74.
  36. Mamas L., Mamas E. Premature ovarian failure and dehydroepiandrosterone. Fertil. Steril. 2009; 91: 644-6.
  37. Nybo Andersen A.M., Wohlfahrt J., Christens P., Olsen J., Melbye M. Maternal age and fetal loss: population register linkage study. Br. Med. J. 2000; 320:1708-12.
  38. Patrizio P., Leong M. Survey: Poor responders: How to define, diagnose and treat? http://www.ivf-worldwide.com/survey/ survey-poor-responders.htm.
  39. Qiao J., Feng H.L. Extra- and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence. Hum. Reprod. Update. 2010; 17:17-33.
  40. Sander V., Lucchetti C.G., Solano M.E., Elia E., Di Girolamo G., Gonzalez C., Motta A.B. Role of the N,N’-dimethylbiguanide metformin in the treatment of female prepuberal BALB/c mice hyperandrogenized with dehydroepiandrosterone. Reproduction. 2006; 131: 591-602.
  41. Schultz R.M., Montgomery R.R., Ward-Bailey P.F., Eppig J.J. Regulation of oocyte maturatation in the mouse: possible roles of intercellular communication, cAMP, and testosterone. Dev. Biol. 1983; 95: 294-304.
  42. Shi X., Li N., Liao C., Shu Q., Zhu F. Glucocorticoid or androgen for autoimmune premature ovary failure in mice. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2009; 34: 576-81.
  43. Simoncini T., Mannella P., Fornari L., Varone G., Caruso A., Cenazzani A.R. Dehydroepiandrosterone modulates endothelial nitric oxide synthesis via direct genomic and nongenomic mechanisms. Endocrinology. 2003; 144(8): 3449-55.
  44. Smith D.M., Tenney D.Y. Effects of steroids on mouse oocyte maturation in vitro. J. Reprod. Fertil. 1980; 60: 331-8.
  45. The 2008 position statement of the North American Menopause Society (NAMS). 2008: 10-23.
  46. Tulandi N., Gelfand M.M. Androgens and reproductive aging. London; New York: Taylor and Francis Group. 2006; 179.
  47. Wallace W.H., Kelsey T.W. Human ovarian reserve from conception to the menopause. PLoS One. 2010; 5(1): e8772.
  48. Wiser A., Gonen O., Ghetler Y., Shavit T., Berkovitz A., Shulman A. Addition of dehydroepiandrosterone (DHEA) for poor-responder patients before and during IVF treatment improves the pregnancy rate: a randomized prospective study. Hum. Reprod. 2010; 25: 2496-500.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies